NEUVASQ BIOTECHNOLOGIES
0762.966.663 · rovalta.com · 26/09/2026
ACTIVE
NEUVASQ BIOTECHNOLOGIES
Financial year 2025 · Closed on 31/12/2025
Net result-2,6 M €-3,1 %over 1 year
Gross margin641,6 k €+15,3 %over 1 year
Equity6,3 M €+61,4 %over 1 year
Workforce9,3 ETP+13,4 %over 1 year
Overview
Identity
Source · BCE/KBONEUVASQ BIOTECHNOLOGIES is a Public limited company incorporated in 2021. Its registered office is in Charleroi. It employs on average 9,3 ETP workers (FTE).
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0762.966.663
- Incorporation
- 05/02/2021
- Legal form
- Public limited company
- Registered office
- Rue Auguste Piccard 48
6041 Charleroi · WallonieSee on map - Contributed capital
- 15 006 000,00 €
- Latest accounts
- 31/12/2025
- Average workforce
- 9,3 ETP
Joint committees (1)
- 207
Signals
Solid equityLow riskGood liquidityHealthy social debts
Financials
Source · NBB, 6 filingsTrend over 5 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 641,6 k € | +15.3% | 556,5 k € | +17.1% | 475,4 k € | +318% | -218,5 k € | -71.5% | -127,4 k € |
| EBITDA | -396,2 k € | -43.5% | -276,1 k € | -14.1% | -242 k € | +52.8% | -512,7 k € | -199% | -171,4 k € |
| Operating result | -2,7 M € | -2.6% | -2,6 M € | -24.3% | -2,1 M € | -85.1% | -1,1 M € | -138% | -475,7 k € |
| Net result | -2,6 M € | -3.1% | -2,5 M € | -25.8% | -2 M € | -80.1% | -1,1 M € | -140% | -463,8 k € |
| Balance sheet | |||||||||
| Equity | 6,3 M € | +61.4% | 3,9 M € | +174% | 1,4 M € | -58.4% | 3,4 M € | -24.5% | 4,5 M € |
| Total assets | 7,2 M € | +67.9% | 4,3 M € | +33.0% | 3,2 M € | -12.8% | 3,7 M € | -19.7% | 4,6 M € |
| Cash | 6 M € | +96.8% | 3 M € | +132% | 1,3 M € | -58.4% | 3,1 M € | -28.6% | 4,4 M € |
| Debts | 917,5 k € | +132% | 395,2 k € | -78.1% | 1,8 M € | +546% | 279,8 k € | +259% | 78 k € |
| Other | |||||||||
| Workforce | 9,3 ETP | +13.4% | 8,2 ETP | +15.5% | 7,1 ETP | +145% | 2,9 ETP | +383% | 0,6 ETP |
Valuation
Indicative valuation
As an indication, this company is worth
between 5 M€ and 10 M€
See the valuationBoard of directors
Source · NBB, accounts to 31/12/20257 active · 15 ended
Active mandates
Active
Yves Ribeill
ActiveActive
Active
Benoit Vanhollebeke
ActiveEnded mandates
Other companies at this address
Rue Auguste Piccard 48 6041 Charleroi| Company | CBE no. |
|---|---|
CANCER STATE THERAPEUTICS● Active | 0793.113.273 |
European Infrared Technologies● Active | 0643.646.468 |
Genflow Biosciences● Active | 0753.904.685 |
HEARTKINETICS● Bankrupt | 0728.461.387 |
SYNABS● Active | 0637.716.206 |
T-knife Therapeutics● Active | 1037.005.620 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 04/02/2021 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 11 months |
| Filing date | 23/06/2026 | 25/11/2025 | 15/07/2024 | 31/08/2023 | 22/08/2022 |
| General meeting | 18/06/2026 | 22/07/2025 | 19/06/2024 | 02/06/2023 | 15/06/2022 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 6 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 18/06/2026 | 23/06/2026 | French | |
| Abridged modelCorrection | 31/12/2024 | 22/07/2025 | 25/11/2025 | French | |
| Abridged model | 31/12/2024 | 22/07/2025 | 13/10/2025 | French | |
| Abridged model | 31/12/2023 | 19/06/2024 | 15/07/2024 | French | |
| Abridged model | 31/12/2022 | 02/06/2023 | 31/08/2023 | French | |
| Abridged model | 31/12/2021 | 15/06/2022 | 22/08/2022 | French |
Valuation
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 5 M€ and 10 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20257 active · 15 ended
Active mandates
Active
Yves Ribeill
ActiveActive
Active
Benoit Vanhollebeke
ActiveEnded mandates
Ownership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Other02/07/2026DIVERS
- Mandates24/10/2025DEMISSIONS, NOMINATIONS
- Capital / shares11/07/2025STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
- Mandates30/09/2024DEMISSIONS, NOMINATIONS
- Other26/09/2024DIVERS
- Capital / shares10/05/2024STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
- Other23/04/2024STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
- Other21/06/2023DIVERS
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-2,6 M €↓
- 2024Annual accounts 2024-2,5 M €↓
- 2024Name changeNeuvasq
- 2023Annual accounts 2023-2 M €↓
- 2022Annual accounts 2022-1,1 M €↓
- 2021Annual accounts 2021-463,8 k €
- 05/02/2021IncorporationPublic limited company
- 2021Name changeNeuvasq Biotechnologies